Merck wins Indian injunction against Januvia copycats

Merck's ($MRK) Indian unit won an injunction in a patent fight over its diabetes drugs Januvia and Janumet, blocking generic versions of the two drugs to be made by Indian drugmaker Aprica Pharmaceuticals. It's one of the few recent patent court decisions there in favor of Big Pharma. Report

Suggested Articles

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

A U.S. appeals court called Maryland's groundbreaking price-hike law unconstitutional, sending legislators back to the drawing board.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.